IL2 and influenza: Although all patients receiving sunitinib or sorafenib developed seroprotection to influenza vaccination comparable with controls, functional T-cell activity was only observed in three groups, rather than patients treated with sorafenib, evidenced by a decreased proliferation rate and IFN-γ/IL-2 production and increased IL-10 level compared with healthy controls.